The effect of insulin-loaded chitosan particle-aggregated scaffolds in chondrogenic differentiation by Malafaya, P. B. et al.
The Effect of Insulin-Loaded Chitosan Particle–Aggregated
Scaffolds in Chondrogenic Differentiation
Patrı´cia B. Malafaya, Ph.D.,1,2 Joa˜o T. Oliveira, Ph.D.,1,2 and Rui L. Reis, Ph.D.1,2
Osteochondral defect repair requires a tissue engineering approach that aims at mimicking the physiological
properties and structure of two different tissues (cartilage and bone) using a scaffold–cell construct. One ideal
approach would be to engineer in vitro a hybrid material using a single-cell source. For that purpose, the scaffold
should be able to provide the adequate biochemical cues to promote the selective but simultaneous differenti-
ation of both tissues. In this work, attention was paid primarily to the chondrogenic differentiation by focusing
on the development of polymeric systems that provide biomolecules release to induce chondrogenic differen-
tiation. For that, different formulations of insulin-loaded chitosan particle–aggregated scaffolds were developed
as a potential model system for cartilage and osteochondral tissue engineering applications using insulin as a
potent bioactive substance known to induce chondrogenic differentiation. The insulin encapsulation efficiency
was shown to be high with values of 70.37! 0.8%, 84.26! 1.76%, and 87.23! 1.58% for loadings of 0.05%, 0.5%,
and 5%, respectively. The in vitro release profiles were assessed in physiological conditions mimicking the cell
culture procedures and quantified by Micro-BCA! protein assay. Different release profiles were obtained that
showed to be dependent on the initial insulin-loading percentage. Further, the effect on prechondrogenic
ATDC5 cells was investigated for periods up to 4 weeks by studying the influence of these release systems on
cell morphology, DNA and glycosaminoglycan content, histology, and gene expression of collagen types I and II,
Sox-9, and aggrecan assessed by real-time polymerase chain reaction. When compared with control conditions
(unloaded scaffolds cultured with the standard chondrogenic-inducing medium), insulin-loaded scaffolds up-
regulated the Sox-9 and aggrecan expression after 4 weeks of culture. From the overall results, it is reasonable to
conclude that the developed loaded scaffolds when seeded with ATDC5 can provide biochemical cues for
chondrogenic differentiation. Among the tested formulations, the higher insulin-loaded system (5%) was the
most effective in promoting chondrogenic differentiation.
Introduction
Osteochondral defects affect both the articular carti-lage and the underlying subchondral bone in the joint
area and may inflict pain and limited mobility, thereby
compromising quality of life. The requirements for a suc-
cessful regeneration of an osteochondral defect could po-
tentially be met by using a tissue-engineered osteochondral
(bone–cartilage) composite of predefined size and shape,
generated in vitro using autologous cells. In this sense, vari-
ous strategies have been reported that result from the use of
one or more cell types cultured into single-component or
more complex scaffolds in a broad spectrum of compositions
and biomechanical properties as recently reviewed.1,2 The
most attractive approach seems to be the design of a suitable
single scaffold that will provide differentiated and adequate
conditions for guiding the growth of the two tissues, ful-
filling their different biological and functional requirements.
Ideally, the scaffold must be able to provide the different and
appropriate differentiation cues to promote an adequate
development of both cartilage and bone tissues, so that the
final hybrid construct can be achieved with the same cell
source.
Several works3–7 can be found reporting the use of dif-
ferent biomolecules to promote the cell differentiation either
as supplements of the culture medium or as loaded in the
scaffolds. For instances, Martin et al.7 have applied specific
regulatory molecules to selectively differentiate bone marrow
stromal cells into either cartilaginous or bone-like tissues in
conjunction with three-dimensional porous polymeric struc-
tures. The work shows that using appropriate chondrogenic
(dexamethasone, insulin, and transforming growth factor-b1)
or osteogenic (dexamethasone and b-glycerophosphate) me-
dium supplements, the generated extracellular matrix (ECM)
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was cartilaginous (containing collagen type II and sulfated
glycosaminoglycans [GAGs]) or bone like (containing os-
teocalcin, osteonectin, and mineralized foci) after 4 weeks of
culture.7
Nevertheless, several studies4,8,9 address the osteochon-
dral defects regeneration by promoting the repair of articular
cartilage that can be further enhanced with controlled release
technology approaches. Chondrogenic cells arise from plur-
ipotential mesenchymal stem cells through a series of dif-
ferentiation pathways, which are being extensively studied.
Subsequently, it has been shown that a number of cytokines
and transcription factors are involved in chondrocyte mat-
uration and cartilage formation; however, the specific mech-
anisms regulating these processes remain unclear.10 Cell
culture is a basic experimental approach used in cellular
and molecular biological studies of chondrocytes.10–14 The
manipulation of the culture environment for chondrocytes
presents the most feasible mechanism for optimizing cell
behavior and phenotype. Various studies have illustrated
the benefits of growth factor integration in establishing and
maintaining the phenotype during in vitro cultivation.10,12
Among all the growth factors known to be involved in
chondrogenesis, insulin-like growth factor (IGF)-1 is consid-
ered to be the main anabolic growth factor of normal
cartilage,12 playing an important role in the growth and dif-
ferentiation of articular cartilage while also promoting chon-
drogenic differentiation of mesenchymal cells.15 IGF-1
belongs to the IGF family of peptide hormones including re-
laxin and insulin and has a single polypeptide homologous to
proinsulin.10 Insulin has not only a great structural similarity
to IGF-1but also a functional similarity, andalso elicitsmarked
response in cartilage.13,16 It has been demonstrated that in
cartilage, the insulin receptor is distinct from the IGF-1 re-
ceptors, but that both proteins interact with other’s receptors
although with significantly lower affinity than those display
for their own cognate receptors.13 While several studies12,14,17
have demonstrated the biological effect of IGF-1 on chon-
drocytes, the physiological effect of insulin on these cells has
not been fully demonstrated. This is due to the potential
combined presence of insulin receptors, IGF-1 receptors, and
hybrid receptors (which contain both insulin and IGF-1 re-
ceptors components). In addition, insulin and IGF-1 can bind
each other’s receptors and hybrid receptors can bind both
growth factors. The ATDC5 cell line, a well-characterized
chondrogenic cell line, is routinely induced to differentiate
into chondrocytes by exposing the cells to high concentrations
of insulin.18 This insulin concentration is presumed to exert its
effects through the IGF-1 receptors with approximately 100-
fold lower affinity that IGF-1.18,19 Phornphutkul et al.13 have
reported that insulin is indeed a physiological regulator of
chondrogenesis, and that its actions are also mediated by the
insulin receptor. In this study, the authors have concluded
that insulin is a potent differentiating agent, but not a potent
mitogen as IGF-1 for chondrocytes.13 In addition, both pro-
liferating and differentiating ATDC5 cells express insulin re-
ceptors at the protein level.13
It is commonly accepted that investigation of novel sys-
tems would benefit from a readily cost model protein such as
insulin since the high costs of growth factors often limit the
development of new systems. Its incorporation in the scaf-
folds as controlled release system appears as an attractive
strategy for chondrogenic differentiation since it will further
allow for selective differentiation required for osteochondral
tissue engineering.
Since active biomolecules are normally used as medium
supplements7 or administrated together at implantation site,20
its incorporation in the scaffolds as controlled release systems
has become a commonly used strategy.4,21,22 This is due to the
fact that a single-dose application intraoperatively cannot
guarantee a prolonged local protein concentration to achieve
permanent stimuli on tissue differentiation, as demonstrated
by Gotterbarm et al.20 They observed that additional local
deposition of liquid growth factors improved the cartilage
repair tissue quality at 12 weeks but had not significantly
influenced the outcome at 52 weeks. Therefore, release tech-
nologies are useful approaches to ensure local release of
growth factors over a certain period of time to further im-
prove the quality of the target tissue.
For most tissue engineering applications, a scaffold
material is required to not only provide a temporary three-
dimensional support and framework to form the desired
tissues, but also act as a carrier for relevant signal molecules.
From the variety of materials that were already investigated,
natural materials appear as key candidates due to their
properties.22–25 Among them, chitosan is being extensively
studied,9,26–28 namely, for cartilage tissue engineering due to
its structural similarity with various GAGs found in articular
cartilage, making it an elite scaffolding material for this ap-
plication. Chitosan structurally resembles GAGs consisting
of long chain, unbranched, repeating disaccharide units re-
garded to play a key role in regulating the expression of the
chondrocytic phenotype and in supporting chondrogenesis
in vitro as well as in vivo.29 The cationic nature of chitosan
also allows for electrostatic interactions with anionic GAGs
and proteoglycans distributed widely throughout the body
and other negatively charged species.30 This property is one
of the important elements for tissue engineering applications
because a number of cytokines=growth factors are known
to be modulated by GAGs.27 Further, it has been applied as
a controlled release system mostly for transforming growth
factor-b1 in cartilage tissue engineering.29–31 Chitosan has
adequate properties such as biocompatibility, biodegrad-
ability, antibacterial, and wound-healing activity.27 It is a
promising candidate owing to their porous structure, gel-
forming properties, ease of chemical modification, and high
affinity to in vivo macromolecules.
The present work describes the development and charac-
terization of insulin-loaded chitosan particle–aggregated
scaffolds as controlled release systems for chondrogenic
differentiation to be further applied in osteochondral tissue
engineering. The in vitro assessment of the release profiles of
the different formulations was carried out in physiological
conditions mimicking the cell culture procedures. Further,
the effect on prechondrogenic ATDC5 cells was investigated
for different periods studying the influence on cell mor-
phology and proliferation, GAG content, and expression of
relevant genes assessed by real-time polymerase chain reac-
tion (PCR).
Materials and Methods
Scaffold production
The scaffolds were produced as described elsewhere.26
Briefly, chitosan (medium molecular weight and of deacety-
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lation degree&85%) was grinded and dissolved overnight in
acetic acid (1% v=v) to obtain a chitosan solution (2% wt).
After complete dissolution, the chitosan solution was filtered.
Unless otherwise stated, all chemicals were bought from
(Sigma-Aldrich, Lisbon, Portugal) and used as received. For
preparation of insulin-loaded chitosan scaffolds, insulin (from
bovine pancreas with molecular weight*5800Da) solutions
were prepared in HCl (0.1M) for distinct theoretical protein
loadings. The protein solution was mixed with the chitosan
solution to obtain a homogeneous distribution. Insulin theo-
retical loadings were 0.05%, 0.5%, and 5% wt relative to
chitosan for each formulation. The prepared solutions were
extruded through a syringe at a constant rate (10mL=h) to
form chitosan droplets into a NaOH (1M) precipitation bath
where particles with regular diameter were formed. The
chitosan particles were quickly washed with distilled water
until pH 7. The particles were then placed into moulds and
left to dry in an oven at 608C for 3 days. Scaffolds with 3-mm-
height and 5-mm-diameter cylindrical shape were obtained.
Insulin-loaded system characterization
Protein loading and encapsulation efficiency. Protein
loading and encapsulation efficiency were calculated by an
indirect procedure. After the loaded-particle preparation
(n¼ 3) as described previously, particles were separated from
the precipitationmedium by filtration, and the aqueous phase
was sampled for insulin quantification. Nonloaded scaffolds
were used as control. The particles were left to dry in amold at
608C, and weighed. The non-loaded-free insulin was deter-
mined by Micro-BCA! (Micro BCA! Protein Assay Kit
23235; Pierce Biotechnology, Rockford, IL). This assay com-
bines the well-known reduction of Cu2þ to Cu1þ by protein in
an alkaline medium with the highly sensitive and selective
colorimetric detection of the cuprous cation (Cu1þ) by bi-
cinchoninic acid. The quantification procedure was per-
formed according to the supplier instructions. Briefly, 150mL
of each of standards, controls, and samples were placed in
triplicate in a 96-well microplate with 150mL of working re-
agent supplied in the kit was added to each well. The plate
was then mixed thoroughly on a plate shaker for 30 s. The
plate was covered and incubated at 378C for 2 h, and cooled to
room temperature; the absorbance was measured at 562 nm
on a microplate reader (Synergy HT; BioTek Instruments
Limited, Bedfordshire, United Kingdom). The readings were
then subtracted of the control (nonloaded scaffolds) and an-
alyzed with respective software (KC4 Microplate Data Ana-
lysis Software; BioTek Instruments Limited, Bedfordshire,
United Kingdom). A standard curve was then plotted
with different insulin concentrations (0, 0.5, 1, 2.5, 5, 10, 20, 40,
and 200mg=mL) to determine the insulin concentration of
each unknown sample. Samples dilutions were used when
necessary. Protein loading was defined as the mass of protein
per unit mass of particles as shown in Equation 1, and the
encapsulation efficiency is calculated according to Equation 2.
Protein loading (%)¼ m1$mr
mp
· 100 (1)
Encapsulation efficiency (%)¼ m1$mr
m1
· 100 (2)
where ml corresponds to the initially loaded weight of pro-
tein, mr is the weight of protein in the precipitation solution,
and mp is the weight of the dry particles prior to in vitro
release studies.
In vitro insulin release studies. In vitro release studies
were carried out mimicking the cell culture conditions de-
scribed in the following section. Each insulin-loaded scaffold
formulation was placed in a 24-well microplate with 1.5mL
of phosphate-buffered saline (PBS). The in vitro release stud-
ies were carried out in triplicate at physiological conditions
(pH 7.4 and 378C). Nonloaded scaffolds were used as con-
trols. At predetermined periods and according to the me-
dium replacement in cell culture studies, aliquots (1mL) of
the supernatant were withdrawn and frozen at $208C for
further protein quantification. The release medium was to-
tally replaced by fresh PBS mimicking cell culture conditions
for total medium replacement. The protein quantification
wasperformedusingMicro-BCA (MicroBCA!ProteinAssay
Kit 23235; Pierce Biotechnology, Rockford, IL) according to
the supplier instructions as described previously.
ATDC5 cells culture in insulin-loaded scaffolds
Cell culture. Cells used in these experiments were a pre-
chondrogenic murine mesenchymal cell line (ATDC5) pur-
chased from the European Collection of Cell Culture (ECACC;
Salisbury, United Kingdom), which differentiates into mature
chondrocytes in the presence of insulin.32 Cells were plated
into tissue culture flasks and incubated at 378C in a humidi-
fied atmosphere of 5% CO2 in air for expansion. ATDC5 cells
were grown as monolayer cultures in a culture medium
consisting of 1:1 mixture of Dulbecco’s modified Eagle’s
medium and Ham’s F-12 nutrient mixture with 15mM
HEPES, sodium bicarbonate, 10,000 units=mL penicillin,
10,000mg=mL streptomycin, 0.365 g=L L-glutamine, and 5%
(v=v) fetal bovine serum (FBSHeat Inactivated; BiochromLtd,
Cambridge, United Kingdom) (DMEM=F12). When the ade-
quate cell number was obtained, cells at passage 8 were
trypsinized, centrifuged, and resuspended in the cell culture
medium. For the control group with nonloaded scaffolds,
the standard chondrogenic medium was used that com-
prised DMEM=F12 supplemented with 10 mg=mL of insulin
(DMEM=F12=INS). Cells were seeded at a density of
100,000 cells=scaffold under static conditions using, for this
purpose, aliquots of 100 mL loaded onto the top of the scaffolds
that had been previously placed in 24-well nonadherent tissue
culture plates. Two hours after seeding, 1.5mL of the re-
spective cell culture medium according to Table 1 was added
to each well, and the cell-seeded scaffolds were cultured for 2
and 4 weeks in a humidified atmosphere at 378C, containing
5% CO2. The culture medium was changed every 3–4 days
until the end of experiments.
Cell adhesion and morphology. Cell adhesion, mor-
phology, and average distribution were observed by scan-
ning electron microscopy analysis. Briefly, the cell–scaffold
constructs were washed in PBS and fixed in 2.5% glutaral-
dehyde (in PBS). The constructs were then rinsed in PBS
again, and subjected to 15min immersion cycles into series of
increasing ethanol concentrations (30%, 50%, 70%, 90%, and
100% ethanol), each to dehydrate the samples. The samples
were finally subjected to critical-point drying by double
immersion into hexamethyldisilazane reagent for 15min
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each, air-dried, and sputter coated with gold (Jeol Ion Sputter
JFC-1100, Jeol, Tokyo, Japan) and analyzed with a Leica
Cambridge S360 scanning electron microscope (Leica Cam-
bridge Lda, Cambridge, United Kingdom).
DNA quantification. DNA quantification was carried out
using PicoGreen" dsDNA Quantitation reagent (Invitrogen
SA, Barcelona, Spain) according to the supplier’s protocol.
Briefly, the cell–scaffold systems were collected at predefined
time periods, placed into Eppendorf tubes with 1mL ultra-
pure water, and kept at 378C for 1 h. Theywere then subjected
to two to three cycles of freezing–thawing to assure that the
entire DNA would be in solution. Standards of double-
stranded DNAwere prepared using ultrapure water with the
following concentrations: 0, 0.2, 0.5, 1, and 2 mg=mL. Chitosan
scaffolds without cells were used as controls. Standards,
controls, and samples were placed in 96-well plates in tripli-
cate according to kit instructions where each single well
contained 200mL of the total mixture solution. The plates were
submitted to a 10min incubation cycle in the dark. Emitted
fluorescence was read using amicroplate reader (SynergyHT;
BioTek Instruments Limited, Bedfordshire, United Kingdom),
and the data were recorded for analysis with the software
(KC4Microplate Data Analysis Software; BioTek Instruments
Limited, Bedfordshire, United Kingdom) (at excitation of
485=20 nm and emission of 528=20 nm).
GAG quantification. Proteoglycan amount was deter-
mined by measuring the level of sulfated GAGs using the
dimethylmethylene blue metachromatic assay. GAG levels
in solution can be quantified using the basic dye, 1,9-
dimethylmethylene blue, which binds to GAGs generating a
metachromatic shift that peaks at A525–530 that can be mea-
sured spectrophotometrically. Briefly, the constructs (n¼ 3)
were immersed in a digestion solution with papain and
N-acetyl cysteine and incubated at 608C overnight. After di-
gestion was completed, the tubes were centrifuged at
13,000 rpm for 10min, and the supernatant was collected.
Chondroitin sulfate standard solutions were prepared with
different concentrations (0, 2.5, 5, 10, 15, 20, 25, 30, 35, 40, 45,
and 50mg=mL) to establish the calibration curve for unknown
sample quantification. Chitosan scaffolds without cells were
used as controls. Standards, controls, and samples (20 mL)
were placed in triplicate in a 96-well plate, and then 250mL of
1,9-dimethylmethylene blue solution was added to each well.
The optical density was measured at 530 nm using a micro-
plate reader (Synergy HT; BioTek Instruments Limited, Bed-
fordshire, United Kingdom), and the data were analyzedwith
software (KC4 Microplate Data Analysis Software, BioTek
Instruments Limited, Bedfordshire, United Kingdom).
Histological analysis. Concerning the histological analy-
sis, hematoxylin–eosin (H&E) staining and toluidine blue
staining were performed on 10-mm-thick sections of cell–
scaffold constructs (n¼ 3) collected at different periods of
culture. The samples were fixated by immersion for 30min in
glutaraldehyde 2.5% (v=v) at 48C, and washed in PBS. His-
tological processing was performed using Technovit 7100"
(Heraeus Kulzer GmbH, Hanau, Germany) according to the
supplier protocol, and sections were sliced using a motorized
rotary microtome (Leica RM2155; Leica Biosystems Nussloch
GmbH, Nussloch, Germany). H&E staining was performed
using an automatic processor according to in-house meth-
odology (Leica TP1020-1; Leica Biosystems Nussloch GmbH,
Nussloch, Germany), and toluidine blue staining was per-
formed as follows. Briefly, sections were hydrated in distilled
water and stained in 1% toluidine blue working solution for
2–3min. Afterward, they were washed three times in dis-
tilled water and quickly dehydrated through 95% ethanol
and 100% alcohol. Sections were then cleared in Histoclear"
(National Diagnostics, Atlanta, GA) and mounted using
Microscopy Entellan" (Merck SA, Lisbon, Portugal) for
observation.
Evaluation of gene expression by real-time PCR. Sam-
ples (n¼ 2) were collected at the defined time periods,
quickly frozen in liquid nitrogen, and stored at $808C until
further analysis. RNA was extracted using TRIzol" (Invitro-
gen SA, Barcelona, Spain) according to the supplier protocol.
Briefly, samples of each condition were grinded and me-
chanically homogenized with a mortar and pestle in TRIzol
reagent. Afterward, chloroform was added, and the samples
were centrifuged to establish a three-phase composition in
the tube. The aqueous phase was collected and put in a
new tube where isopropanol was added. The samples were
once again centrifuged, the supernatant was discarded, and
the pellet was washed with 75% ethanol. The samples were
again centrifuged, let to air-dry, and suspended in ultrapure
water for posterior analysis. The amount of isolated RNA
and A260=280 ratio was determined using Nanodrop ND-
1000 Spectrophotometer (NanoDrop products; Thermo Sci-
entific, Wilmington, DE). After these determinations, 1mg of
RNA of each sample was reverse transcribed into cDNA
using the IScript! cDNA synthesis kit (Bio-Rad Laboratories
Lda, Lisbon, Portugal) in an MJ Mini! Personal Thermal
Cycler (Bio-Rad Laboratories Lda, Lisbon, Portugal). Carti-
lage-related markers were chosen to evaluate the chondro-
genic phenotype of the cultured systems. These included
collagen type I, collagen type II, Sox-9, and aggrecan, using
GAPDH as the housekeeping gene for normalization. The
expression of each gene was normalized to the GAPDH
value in that sample. All the primer sequences were gener-
ated using Primer3 software and acquired from MWG
Eurofins MWG Operon (Ebersberg, Germany). More details
can be found in Table 2. Real-time PCR was performed using
SYBR Green IQ! Supermix (Bio-Rad Laboratories Lda, Lis-
bon, Portugal) to detect amplification variations in an MJ
Mini Personal Thermal Cycler (Bio-Rad Laboratories Lda,
Table 1. Scaffold Formulations and the Respective
Cell Culture Medium
Scaffolds Formulation Culture medium
C Nonloaded (control group) DMEM=F12=INS
0.05 Loaded with 0.05% (wt=wt)
insulin
DMEM=F12
0.5 Loaded with 0.5% (wt=wt)
insulin
DMEM=F12
5 Loaded with 5% (wt=wt)
insulin
DMEM=F12
DMEM, Dulbecco’s modified Eagle’s medium; F12, Ham’s F-12
nutrient mixture with 15mM HEPES; INS, DMEM=F12 supple-
mented with 10 mg=mL of insulin.
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Lisbon, Portugal) machine. The results were analyzed using
MJ Opticon Monitor 3.1 software (Bio-Rad Laboratories Lda,
Lisbon, Portugal).
Statistical analysis
When applicable, the statistical analysis of values obtained
with the several characterization techniques was carried out
using Student’s two-tailed t-test with a confidence level
of 99.5%. All statistical calculations were performed with
Analysis ToolPak software. p-Values below 0.05 were con-
sidered statistically significant.
Results
Insulin-loaded chitosan scaffolds
Protein loading and encapsulation efficiency. The de-
veloped insulin-loaded scaffolds were characterized by as-
sessing the encapsulation efficiency and protein loading as
shown in Figure 1. Insulin loadings of the scaffolds were
0.0297! 0.0001%, 0.3843! 0.0118%, and 3.9911! 0.1159%, as
determined by Micro-BCA!, and correlated well with the
intended and designed insulin theoretical loadings of 0.05%,
0.5%, and 5%, respectively. The obtained encapsulation ef-
ficiencies were high with values of 70.37! 0.80%, 84.26!
1.76%, and 87.23! 1.58% for insulin loadings of 0.05%, 0.5%,
and 5%, respectively.
In vitro release studies. The release of insulin from
chitosan particle–aggregated scaffolds under physiological
conditions was investigated with total medium replacement
at the same intervals of cell culture medium replacement
(3 or 4 days). The assays were performed in this way to
mimic exactly the cell culture conditions. The obtained re-
lease profiles represented in Figure 2 were characterized by
an initial rapid release within the first 4 days with values
around 80% and 60% of released insulin for 0.05% and 0.5%
formulations, respectively. This burst effect was less pro-
nounced for the 5% insulin-loaded scaffolds with a 40% re-
lease in the same initial immersion period. The cumulative
release profile shown to be dependent on the initial scaffolds
loading, being the release rate slower for higher initial insulin
concentrations. For the 0.05% formulation, the remaining
20% insulin was almost totally released until day 11. Further,
the release behavior of the 0.5% appeared similar since more
than 60% of the insulin was released within the first 3 days,
and the remaining 40% insulin was almost released within 18
days. When insulin content increased to 5%, the release rate
decreased and only around 85% insulin was released until
the end of the experiment at 28 days, most likely due to its
high initial concentration.
The insulin release was also plotted considering the insulin
concentrations in the release medium as represented in Figure
3 which are important data, considering the further cell cul-
ture studies. The insulin concentrations released to the me-
dium were, as expected, well correlated with the initial
loading in the respective order of magnitude. The insulin re-
leased to the medium was below 1mg=mL after day 11 and
day 21 for 0.05% and 0.5% formulations, respectively. After
these time periods and for these formulations, lower amounts
of insulin were released and were always below 0.1 mg=mL
until the end of the experiments. In contrast, for higher initial
insulin loading, protein concentrations were kept always
above 80 mg=mL even at the last day of these studies (day 28).
Biological assessment of ATDC5 chondrogenic
differentiation by insulin-loaded scaffolds
Cell morphology. To study the effect of insulin-loaded
scaffolds on chondrogenic differentiation, the performance of
the scaffolds was investigated in a long-term cell culture with
a prechondrogenic cell line (ATDC5) for up to 4 weeks. This
study allowed also to assess the bioactivity of incorporated
and released insulin from the scaffolds. The results were
always compared with standard culture conditions, that is,
unloaded scaffolds cultured with the standard chondrogenic
medium. Cell morphology was qualitatively evaluated by
scanning electron microscopy after 2 and 4 weeks of cul-
ture as shown in Figure 4. After 2 weeks of culture, cells
had adhered to the chitosan particle–aggregated scaffolds.
Chondrocyte cells seeded on insulin-loaded chitosan scaffolds
Table 2. Primers Used for Real-Time Polymerase Chain Reaction Evaluation of ATDC5 Gene Expression
Gene Accession 5-Primer 3-Primer
Collagen type I NM_007742 GAGCGGAGAGTACTGGATCG GCTTCTTTTCCTTGGGGTTC
Collagen type II NM_001113515 GCCAAGACCTGAAACTCTGC GCCATAGCTGAAGTGGAAGC
Sox-9 NM_011448 AGCTCACCAGACCCTGAGAA TCCCAGCAATCGTTACCTTC
Aggrecan NM_007424 TGGCTTCTGGAGACAGGACT TTCTGCTGTCTGGGTCTCCT
GAPDH NM_008084 AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA
FIG. 1. Protein loading and encapsulation efficiency of
chitosan particle–aggregated scaffolds loaded with 0.05%,
0.5%, and 5% of insulin. Numbers in white represent the
theoretical loading value. Data are expressed as mean!
standard deviation (n¼ 3).
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proliferated, possessing a rounded typical chondro-
cytic morphology, which is an indication of chondrocyte
differentiation (Fig. 4C, E, G). Cell condensation and for-
mation of ECM were detected as well, since it is also possible
to observe the formation of collagen fibrils.33 In contrast, for
the control group, cells presented a flattened and spread
morphology still showing a fibroblast-like phenotype with
some cytoplasmic extensions (Fig. 4A). However, for 4 weeks
of culture, in all the studied formulations, the cells main-
tained a rounded shape morphology and remained aggre-
gated, being this more clear for the 5% formulation (Fig. 4B,
D, F, H). Nevertheless, it was noticeable that, for 0.05% and
0.5% insulin loading, the cell distribution over the scaffolds
was lower. The formation of ECM including collagen fibrils
was also detected being more evident for the control and for
the 5% insulin formulation, where the cells clustering is also
visible (Fig. 4B, H).
Cell proliferation. For all the developed formulations, cell
proliferation was investigated by DNA quantification after 2
and 4 weeks, and the obtained results are plotted in Figure 5.
After 2 weeks of culture, the total amount of DNA in each
group was 0.042! 0.029mg=sample in the control group,
0.026! 0.002mg=sample in the 0.05% group, 0.063! 0.002
mg=sample in the 0.5% group, and 0.091! 0.008mg=sample in
the 5% group. The amount of DNA presented an increasing
trend for higher insulin loading, where the 5% group is sig-
nificantly higher than other formulations. This increasing
tendency for higher values of insulin loading was maintained
after 4 weeks with all DNA values statistically different, ex-
cept between 0.5% and 0.05% formulation. At 4 weeks, the
obtained values were 0.533! 0.033mg=sample for the control,
0.029! 0.007mg=sample for 0.05%, 0.040! 0.011 mg=sample
for 0.5%, and 0.084! 0.002mg=sample for the 5% insulin
loading group. For longer time periods, there is a decreasing
trend between the same conditions (with the exception of the
control group) compared with shorter periods.
GAG quantification. GAGs are important components of
proteoglycans and are typically present in the cartilaginous
ECM being aggrecan the most relevant in terms of mechan-
ical functionality. GAG content was determined to assess the
formation of newly formed ECM and thus, if occur, the
differentiation of ATDC5 into chondrocytes in these insulin-
FIG. 2. Cumulative insulin release pro-
file for the different formulations of insu-
lin-loaded chitosan scaffolds after
immersion in phosphate-buffered saline
for up to 28 days (4 weeks) with total
medium replacement at determined time
points mimicking the cell culture condi-
tions. Data are expressed as mean!
standard deviation (n¼ 3).
FIG. 3. Insulin concentration in the
release medium for chitosan-loaded scaf-
folds with 0.05%, 0.5%, and 5% of insulin
immersed in phosphate-buffered saline
for up to 28 days (4 weeks) with total
medium replacement every 3 or 4 days
mimicking the cell culture conditions.
Data are expressed as mean! standard
deviation (n¼ 3).
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loaded cell–scaffold constructs, at weeks 2 and 4 (Fig. 6).
The GAG content was calculated per DNA content of each
formulation. The biochemical analysis demonstrated that the
content of GAGs per DNA increased from week 2 to 4 for the
higher insulin initial loadings (0.5% and 5%). Comparing
the results for 2 weeks of culture, one can say that there is a
decreasing tendency with increasing insulin concentrations,
in spite of no statistically significant difference found when
compared with that of the control. In contrast, for 4 weeks
this tendency is inverted with higher GAG contents for
higher insulin concentrations. The values of GAG content
were 54.22! 5.62 mg=mg DNA for control group, 37.08!
25.08mg=mg DNA for 0.05%, 287.57! 86.04mg=mg DNA for
0.5%, and 188.99! 22.55mg=mg DNA for the 5% formulation
after 4 weeks of culture with ATDC5 cells.
Histological examination. Chondrocytes were seeded
onto loaded and unloaded chitosan scaffolds, and the
morphologies were observed histologically upon H&E and
toluidine blue staining of sections from the bulk of the scaf-
folds. Representative sections obtained after 2 and 4 weeks
of culture are shown in Figures 7 and 8 for the standard
FIG. 4. Scanning electron
microscopy microphoto-
graphs of chitosan scaffolds
loaded with 0% (C) (A, B),
0.05% (C, D), 0.5% (E, F), and
5% (G, H) of insulin seeded
with ATDC5 cells and cul-
tured for 2 weeks (A, C, E, G)
and 4 weeks (B, D, F, H).
Magnification, 2000%.
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condition and higher insulin-loading formulation (5%). His-
tological examination of the sections indicated that the
chondrocytes were evenly distributed throughout the scaf-
fold and that the chondrocytes were able to infiltrate, adhere,
and proliferate into the inner pores of the scaffolds. Ana-
lyzing the sections stained with H&E (Fig. 7), one can say
that cells seeded in the insulin-loaded scaffolds have similar
morphology compared with the control condition after 2 and
4 weeks. The cell constructs were composed of viable chon-
drocytes as detected by the H&E–positive staining. The
clustering of chondrocytes was evident after 4 weeks, being
more clear for 5% insulin loading.
Toluidine blue staining showed evidence of viable chon-
drocytes embedded in a newly synthesized ECM as shown
in Figure 8. The histological sections stained mainly meta-
chromatic (purple) indicative of sulfated proteoglycan de-
position at 4 weeks of culture. Some orthochromatic areas
(blue) were also identified, but these were found primarily at
2 weeks of culture. The central matrix stained positively with
toluidine blue, thereby indicating the presence of a cartilag-
inous matrix composed of proteoglycans. The formation of
cell aggregates is once more evident with characteristic la-
cunae of differentiated chondrocytes that were invested with
intense metachromatic matrix as shown in Figure 8B and
D, suggesting the active deposition of proteoglycan after
4 weeks.
Gene expression. Gene expression of type I collagen, type
II collagen, Sox-9, and aggrecan in the loaded constructs after 4
weeks of culture with ATDC5 cells was examined by real-
time PCR and normalized for the control condition (ra-
tio¼ 1). The obtained normalized expression ratios for each
gene are shown in Figure 9. The cells in the constructs ex-
pressed genes encoding collagen type I, Sox-9, and aggrecan
after 4 weeks of culture, except for Sox-9 that was not de-
tected for the 0.05% insulin-loaded formulation. No expres-
sion of collagen type II was identified in any of the groups,
including the standard condition. The normalized ratio of
Sox-9 gene expression of the insulin-loaded scaffolds with
5% group significantly increased compared with the stan-
dard condition. The same tendency is observed for aggrecan
expression, which is also increasing for the higher insulin
loading constructs with a 9.6-fold higher ratio. Concerning
the values for type I collagen expression, there is no statisti-
cally significant difference between the control and the 5%
formulation.
Discussion
Insulin–chitosan system characterization
and in vitro release studies
Chondrocytes experience biochemical stimulation and
mechanical stimulation in vivo that are integral to the de-
velopment and maintenance of cartilage. Growth factors aid
in signaling and regulating cartilage development and ECM
maintenance. Growth factors are present in serum and
synovial fluid, or may be stored in the cartilage matrix for
immediate release when needed. Among these, IGF-1 is
considered to be the main anabolic growth factor of normal
cartilage.12,16 In addition, it is known that insulin has a great
structural and functional similarity to IGF-1 and can bind
to IGF-1 and insulin receptors with a marked response in
cartilage.13,16 Further, local delivery of biochemically active
substances is ideal, since these proteins often have short half-
lives and multiple biological effects with potential systemic
toxicity. Investigation of novel experimental application
systems for growth factors or other bioactive substances in
tissue engineering is often limited by high costs of substances
and would benefit from a defined and easily controllable
model system, namely, using insulin as a differentiation
biomolecule since it is a readily available protein. In addi-
tion, release technology approaches can further improve the
function of active biomolecules, namely, in an in vivo situa-
tion where a single-dose application cannot guarantee a
prolonged local protein concentration. Further, when aiming
at osteochondral applications, systems loaded with different
adequate differentiation agents can be assembled in a bi-
phasic construct, allowing for selective but simultaneous
FIG. 5. DNA quantification for chitosan scaffolds (C)
loaded with 0.05%, 0.5%, and 5% of insulin cultured with
ATDC5 cells for 2 and 4 weeks. The indicated conditions (x)
were found to be not statistically significantly different.
Statistically significant difference was found between the
other conditions ( p< 0.05). Scale was adjusted for better
observation of tendencies.
FIG. 6. Glycosaminoglycan (GAG) quantification for chit-
osan scaffolds (C) loaded with 0.05%, 0.5%, and 5% of insulin
cultured with ATDC5 cells for 2 and 4 weeks. The indicated
conditions (x) were found to be not statistically significantly
different. Statistically significant difference was found be-
tween the other conditions ( p< 0.05).
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differentiation of a single source of stem cells into both
chondrogenic and osteogenic pathways.
Having this in mind, we aimed in this work to incorporate
insulin in a chitosan particle–aggregated scaffold to aid in
cartilage tissue engineering. The future final goal will involve
the incorporation of these insulin systems in osteochondral
biphasic constructs to selectively but simultaneously differ-
entiate the same cell source into the chondrogenic and os-
teogenic lineages. For that purpose, insulin was successfully
incorporated at different concentrations in chitosan matrices
as shown by the obtained high encapsulation efficiencies and
protein loadings.
FIG. 7. Representative his-
tological sections stained
with hematoxylin–eosin of
chitosan-based scaffolds
(A, B) and chitosan-based
scaffolds loaded with 5% in-
sulin (C, D) after 2 (A, C) and
4 weeks (B, D) of culture with
ATDC5 cells. Magnification,
400%. Color images available
online at www.liebertonline
.com=ten.
FIG. 8. Representative his-
tological sections stained with
toluidine blue of chitosan-
based scaffolds (A, B) and
chitosan-based scaffolds loa-
ded with 5% insulin (C, D)
after 2 (A, C) and 4 weeks (B,
D) of culture with ATDC5
cells. Magnification, 400%.
Color images available online
at www.liebertonline
.com=ten.
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It is known that chitosan is positively charged due to the
protonation of the amino groups, and insulin is negatively
charged at pH above its isoelectric point. Consequently,
electrostatic interactions between both materials can be used
as a driving force for insulin incorporation into chitosan
matrices.34 This is one key issue that explains why chitosan
has been widely investigated as carrier for insulin delivery
for other than tissue engineering applications, such as oral
insulin delivery35,36 or self-assembled polyelectrolyte nano-
complexes for intranasal absorption34 or oral delivery.37 The
obtained real protein loading values correlated well with the
intended insulin theoretical loadings, in spite of the slight
insulin loss that can be attributed to the washing procedure
required for the particle-aggregated scaffold production. In
the same way, the encapsulation efficiencies were also high.
These values shown to be dependent on the insulin content,
increasing for higher initial insulin concentrations in the
scaffolds. The same dependence was observed for the release
profiles that correlated well in terms of order of magnitude
with the initial insulin loading. For lower initial insulin
contents, there was a burst release on the first days of im-
mersion. Nevertheless, insulin levels in the release medium
were above 1 mg=mL until day 11 for 0.05% formulation and
day 21 for 0.5%. This burst effect was less evident for the
higher insulin-loaded scaffolds that, in general, presented
best performance in the biological tests. For the higher initial
loading, insulin concentration in the medium was above
80 mg=mL until the end of the experiment. The insulin
monomer contains many ionizable groups, due to 6 amino
acid residues capable of attaining a positive charge and 10
amino acid residues capable of attaching a negative charge.38
These properties are, therefore, possibly responsible for the
entrapment of insulin into chitosan matrices due to the
electrostatic interaction between the protein and the poly-
anion that might also favor the retention of insulin within the
chitosan matrix.39
Biological assessment of ATDC5 chondrogenic
differentiation by insulin-loaded scaffolds
Cell morphology. There are several studies7,19 reporting
the use of insulin for cartilage tissue engineering. The most
typical approach is obviously the use of insulin as a differ-
entiating agent in the cell culture medium, and it is used
nowadays as a standard condition in the chondrogenic dif-
ferentiation medium. The group of Gopferich19,40,41 has been
working in different strategies, including this standard ap-
proach,19 but also going from the incorporation of insulin-
loaded microspheres into fibrin hydrogels with encapsulated
chondrocytes41 to the development of lipidic cylinders that
are placed together with the seeded scaffolds for insulin-
controlled release.40 The reported studies show in a general
way that insulin is able to promote cartilage formation by
improving the quality of the cartilaginous constructs, since it
increases the collagen content and promotes GAG deposi-
tion.40,41 Nevertheless, to the best of our knowledge, this is
the first study with direct insulin encapsulation into tissue
engineering scaffolds.
In this study, the bioactivity of the released insulin as well
as its influence on chondrogenic differentiation was studied
with long-term culture of ATDC5 cells for a period up to 28
days. ATDC5 cells are an example of a prechondrogenic stem
cell line and reproduce the differentiation stages of chon-
drocytes.10 In monolayer culture and only in presence of in-
sulin (or other chondrogenic differentiation agent), ATDC5
cells retain the properties of chondroprogenitor cells that are
at the early phase of differentiation and form cartilage nod-
ules when cells reach condensation.18 The cartilage nodules
enlarge while chondrocytes proliferate, for about 2 weeks in
culture. The ATDC5 cell line is the first example to display the
entire spectrum of chondrocyte differentiation.10 Our results
showed that ATDC5 cells were able to attach and were dis-
persed throughout the scaffolds after 2 weeks of culture.
Cellular condensation was observed for the insulin-loaded
scaffolds, which is one of the key events in chondrogenesis.42
The capability of chondrocytes to synthesize and retain their
matrix in close cell proximity is the basis of the chondrocyte
phenotype and is vitally important in maintaining their
rounded cell shape.3 After 2 weeks of culture in the insulin-
loaded scaffolds, the majority of cells presented a rounded
morphology, whereas in the control condition some flattened
elongated cells could be detected. After 4 weeks of culture,
the cells were already with the typical round chondrocytic
morphology in all the studied groups. The deposition of
newly formed ECM was possible to be observed microscop-
ically, and collagen fibrils were also detected.33
Cell proliferation. Concerning cell proliferation after 2
weeks, the highest concentration insulin (5%) showed to
have a positive effect on DNA content. This effect was in-
verted for longer culture periods, which can be considered as
an indication of cell differentiation events. It is well known
that generally cell differentiation goes along with a reduction
of cell proliferation, since chondrogenesis results from a
complex equilibrium between chondrocyte proliferation and
differentiation.43 This may also be related with the higher
concentration of insulin present in the medium. In the stan-
dard condition, cell–scaffold constructs are exposed to
10 mg=mL of insulin, whereas in the higher concentration
FIG. 9. Normalized gene expression ratio of collagen type I
(col I), Sox-9 (sox9), and aggrecan (agg) assessed by real-time
polymerase chain reaction of chitosan-based scaffolds loaded
with 0% (C), 0.05%, and 5% of insulin cultured with ATDC5
cells for a 4-week period. The ratios were normalized relative
to the control (ratio¼ 1, nonloaded scaffolds cultured with
the chondrogenic medium). The indicated conditions (x)
were not statistically significantly different. Statistically sig-
nificant difference was found between the other conditions
( p< 0.05).
744 MALAFAYA ET AL.
of insulin-loaded scaffolds (5%), the concentration is always
above 80mg=mL. It is known that insulin is a potent differ-
entiating agent, but not a potent mitogen for chondrocytes,13
and this higher concentration may be inhibiting its prolifer-
ative capacity.
GAG quantification. The biochemical analysis demon-
strated that the content of GAGs increased from week 2 to 4
for higher insulin-loading scaffolds, indicating that typical
ECM components were being deposited occur biosynthesis,
thereby confirming the differentiation of the ATDC5 cells
toward the chondrogenic lineage. The GAGs production is
higher for control condition at 2 weeks and 0.5% at 4 weeks
compared with the 5% formulation, due to the lower DNA
content at the respective time periods. On the other hand, in
the control condition, GAG content decreased substantially
from 2 to 4 weeks of culture due to the substantial increase
in cell proliferation in unloaded scaffolds.
Histological examination. Histologically, it was also
possible to observe that the chondrocytes were able to infil-
trate, adhere, and proliferate into the inner pores of the
scaffolds. This reflects the advantageous structural design of
these scaffolds that present a high interconnectivity degree
as characterized in previous works.44,45 Further, toluidine
blue staining demonstrated the typical metachromasia of the
articular cartilage matrix both to the control condition and
5% insulin-loaded scaffolds after 4 weeks of culture. Tolui-
dine blue dyes form complexes with anionic glycoconjugates
such as proteoglycans and GAGs, and its positive staining is
therefore an evidence of proteoglycan deposition for ECM
production.46 Further, the observed morphology is consistent
to that observed with mature chondrocytes, which are pre-
dominantly round cells located in matrix cavities called
lacunae.10
Gene expression. The results of the real-time PCR con-
firmed the mRNA expression of genes encoding the specific
ECM markers for cartilaginous tissue, such as Sox-9 and
aggrecan. The transcription factor Sox-9 is considered to be
a crucial factor in chondrocyte differentiation and cartilage
formation and is required to maintain the chondrocytes
phenotype.10 Aggrecan is a large chondroitin sulfate pro-
teoglycan and one of the main macromolecules constituting
the cartilaginous ECM, which is responsible for the tissues
compressive resistance.10 The cells seeded in high insulin
content scaffolds revealed higher expression of these genes,
suggesting the development of phenotypic characteristics
consistent with chondrocytes. The insulin-loaded scaffolds
with 5% showed a 1.7-fold change significantly higher up-
regulation for Sox-9 and 9.6-fold higher for aggrecan when
compared with the standard condition after 4 weeks of cul-
ture. Sox-9 is known to promote chondrocyte differentiation
in part by activating chondrocyte-specific enhancer elements
in aggrecan.47 This finding is supported by our results, which
showed that insulin-loaded scaffolds induced an increase in
Sox-9 in association with a substantial upregulation of ag-
grecan mRNA. However, Sox-9 is also known to regulate the
expression of collagen type II.10,47 In this study, no expression
of collagen type II was detected for any group. This is prob-
ably related to the fact that in this preliminary study a cell
line was used given the high number of complementary
analyses needed to obtain conclusive results. It is expected
that the expression of collagen type II would increase signifi-
cantly when using primary cells. However, it is known that
chondrocytes can dedifferentiate with change in shape,
production of collagen type I, and changes in the metabolic
pattern of their proteoglycan synthesis.33,43 In the present
paper, the typical round chondrocytic morphology was
maintained after 4 weeks for all the studies groups. Further,
for higher insulin content, the proteoglycan synthesis was
increasing as detected by toluidine blue, and GAG quanti-
fication and the gene expression of Sox-9 and aggrecan
were also higher. Moreover, no significant upregulation in
collagen type I was measured. Further studies would be nec-
essary with primary cells to overcome the absence of ex-
pression of collagen type II expression in all the studied
groups.
Cell culture and tissue culture systems have long been
known to display insulinase activity, which can rapidly and
markedly reduce the effective insulin concentration.13 This is
particularly relevant to the studies in which the long-term
effects on ATDC5 cell differentiation are investigated, such
as the one describe herein. This is a possible explanation
why, from the overall results, the higher insulin concentra-
tion was more effective on promoting chondrogenic differ-
entiation. Nevertheless, there are studies that report that the
insulin receptor can initiate and sustain a differentiation
promoting signal in chondrocytes,13 explaining the slight
biochemical effects of lower insulin content formulations
(0.05% and 0.5%) after 4 weeks, even though the release was
complete.
As an overall remark, one can mention that the most
promising results were obtained with ATDC5 cells seeded in
the higher insulin-loaded scaffolds (5%) that showed a typ-
ical chondrocytic round morphology with visible cell con-
densation. Cells were positively stained by toluidine blue,
presented a high GAGs production, and expressed genes
encoding cartilaginous markers such as Sox-9 and aggrecan,
which suggest the formation of cartilaginous tissue. Further,
in the developed insulin-release systems, the insulin retained
its bioactivity for at least 28 days, which is in agreement
with other reported studies.40,48
Conclusions
This work reports the possibility to incorporate insulin as
a potent substance for cartilage tissue engineering in a chit-
osan particle–aggregated scaffold. It is an easily controllable
in vitro release system using insulin as a model protein, since
its potent differentiating capacity in chondrocytes is well
known. In addition, this approach opens the possibility to
assemble the developed systems in bilayered constructs to
promote selective differentiation of cartilage and bone in
osteochondral applications. The results showed high encap-
sulation efficiencies, well correlated protein loadings, and
adequate release profiles. The chondro-inductive effect of the
insulin-loaded scaffolds was further investigated with long-
term ATDC5 cell culture. The cells seeded in the higher
insulin-loaded scaffolds (5%) showed a round morphology
and were able to synthesize GAGs. ATDC5 stained posi-
tively for proteoglycans and evidenced an upregulation of the
expression profiles of cartilaginous genes Sox-9 and aggrecan
when compared with the standard condition. Therefore, the
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results of this study demonstrate the ability of insulin-loaded
chitosan scaffolds to support chondrocyte attachment and
differentiation, as well as cartilaginous matrix biosynthesis in
a dose-dependent manner, opening interesting prospects for
their use in therapeutical approaches to treat osteochondral
lesions.
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